CD34-selected peripheral blood stem cells

CD34-selected peripheral blood stem cells (PBSCs) are a specialized cellular therapy product consisting of hematopoietic stem and progenitor cells (HSPCs) harvested from a donor's peripheral blood and enriched for the CD34 surface antigen. This enrichment is typically performed ex vivo using immunomagnetic selection systems (such as the Miltenyi Biotec CliniMACS) which utilize monoclonal antibodies against CD34 conjugated to paramagnetic beads. The selection process provides a highly purified graft of hematopoietic stem cells while simultaneously depleting mature T-lymphocytes, B-lymphocytes, and other immune effector cells by several orders of magnitude. In the allogeneic transplant setting, this T-cell depletion is intended to prevent or reduce the incidence of Graft-versus-Host Disease (GVHD) without the need for intensive pharmacological immunosuppression. In the autologous setting, CD34 selection is employed to "purge" the stem cell graft of contaminating malignant cells (e.g., in neuroblastoma) or autoreactive immune cells (e.g., in Crohn's disease or multiple sclerosis), facilitating hematopoietic recovery after high-dose immunoablative or myeloablative therapy while reducing the risk of disease recurrence.

Brand names

CliniMACS CD34 Reagent System

Other names

CD34-selected PBSCCD-34-selected PBSCCD 34-selected PBSCCD34-enriched peripheral blood stem cellsCD-34-enriched peripheral blood stem cellsCD 34-enriched peripheral blood stem cellsCD34+ selected peripheral blood stem cellsCD34-positive PBSCCD-34-positive PBSCCD 34-positive PBSCCD34-selected peripheral blood progenitor cellsCD-34-selected peripheral blood progenitor cellsCD 34-selected peripheral blood progenitor cellsT-cell depleted PBSC graft